The use of pharmacokinetics to improve the treatment of ovarian cancer: combination paclitaxel (TaxolR)-carboplatin
- 1 May 1997
- journal article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 7 (s1) , 14-17
- https://doi.org/10.1046/j.1525-1438.7.s1.7.x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Prediction of Carboplatin Clearance From Standard Morphological and Biological Patient CharacteristicsJNCI Journal of the National Cancer Institute, 1995
- Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1994
- Dose-Intense Taxol: High Response Rate in Patients With Platinum-Resistant Recurrent Ovarian CancerJNCI Journal of the National Cancer Institute, 1994
- Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.Journal of Clinical Oncology, 1993
- Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group.Journal of Clinical Oncology, 1993
- Renal handling of carboplatinCancer Chemotherapy and Pharmacology, 1992
- A phase I trial of taxol given by a 6-hour intravenous infusion.Journal of Clinical Oncology, 1991
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989
- Creatinine Clearance: Bedside EstimateAnnals of Internal Medicine, 1973